Generated Narrative: Citation 267246 version: 12; Last updated: 2025-10-13 12:34:35+0000; Language: en Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: https://fevir.net/resources/Citation/267246 identifier: FEvIR Object Identifier/267246, https://pubmed.ncbi.nlm.nih.gov/11232013 title: 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes. status: Active author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ approvalDate: 2001-04-12 lastReviewDate: 2018-11-30 classification type: Citation Source classifier: MEDLINE classification type: MEDLINE Citation Owner classifier: National Library of Medicine, Index Section currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish statusDate activity: PubMed Pubstatus of Pubmed period: ?? --> 2001-03-07 10:00:00+0000 statusDate activity: PubMed Pubstatus of Medline period: ?? --> 2001-04-17 10:01:00+0000 statusDate activity: PubMed Pubstatus of Entrez period: ?? --> 2001-03-07 10:00:00+0000 citedArtifact identifier: https://pubmed.ncbi.nlm.nih.gov/11232013, https://doi.org/10.1210/jcem.86.1.7157 Titles - Type Text * Primary title Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Abstracts - Type Text * Primary human use This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary end point was change in hemoglobin A(1c); other variables assessed included fasting plasma glucose, fructosamine, endogenous insulin secretion, urinary albumin excretion, serum lipids, and adverse events. Rosiglitazone (2 and 4 mg bd) decreased mean hemoglobin A(1c) relative to placebo by 1.2 and 1.5 percentage points, respectively, and reduced fasting plasma glucose concentrations relative to placebo by 3.22 and 4.22 mmol/L, respectively. Fasting plasma insulin and insulin precursor molecules decreased significantly. Homeostasis model assessment estimates indicate that rosiglitazone (2 and 4 mg bd) reduced insulin resistance by 16.0% and 24.6%, respectively, and improved ss-cell function over baseline by 49.5% and 60.0%, respectively. Urinary albumin excretion decreased significantly in the rosiglitazone (4 mg bd) group. There was no increase in adverse events with rosiglitazone. In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions. relatesTo type: Correction In classifier: Published Erratum citation: J Clin Endocrinol Metab 2001 Apr;86(4):1659 relatesTo type: Correction In classifier: Published Erratum citation: J Clin Endocrinol Metab. 2002 Feb;2(1):iv. publicationForm publishedIn type: Periodical identifier: Print ISSN Type/0021-972X, ISOAbbreviation/J Clin Endocrinol Metab, ISSN Linking/0021-972X, Medline Title Abbreviation/J Clin Endocrinol Metab, NLM Unique ID/0375362 title: The Journal of clinical endocrinology and metabolism publisherLocation: United States citedMedium: Print volume: 86 issue: 1 articleDate: 2001-01 pageString: 280-8 WebLocations - Classifier Url * Abstract https://pubmed.ncbi.nlm.nih.gov/11232013/ classification type: Publishing Model classifier: Print classification type: Chemical classifier: Blood Glucose, Hypoglycemic Agents, Thiazoles, Thiazolidinediones, Rosiglitazone classification type: MeSH heading artifactAssessment: ArtifactAssessment: artifact[x] = this resource classification type: Publication type classifier: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial classification type: Knowledge Artifact Type classifier: Journal Article artifactAssessment: Classifier added by Computable Publishing LLC classification type: Citation subset classifier: IM contributorship complete: true entry contributor: Lebovitz HE forenameInitials: HE affiliation: Department of Medicine, State University of New York, Brooklyn, New York 11203, USA. hlebovitz@attglobal.net entry contributor: Dole JF forenameInitials: JF entry contributor: Patwardhan R forenameInitials: R entry contributor: Rappaport EB forenameInitials: EB entry contributor: Freed MI forenameInitials: MI entry contributor: Rosiglitazone Clinical Trials Study Group Generated Narrative: Practitioner #contributor0 name: H E Lebovitz Generated Narrative: Practitioner #contributor1 name: J F Dole Generated Narrative: Practitioner #contributor2 name: R Patwardhan Generated Narrative: Practitioner #contributor3 name: E B Rappaport Generated Narrative: Practitioner #contributor4 name: M I Freed Generated Narrative: Organization #contributor5 name: Rosiglitazone Clinical Trials Study Group Generated Narrative: ArtifactAssessment #meshHeading0 artifact: Citation 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes. content type: components (if present) include qualifier codings classifier: Aged freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Aged, 80 and over freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Blood Glucose freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: analysis Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Diabetes Mellitus, Type 2 freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: blood Components - Type Classifier * is Major topic No component type: qualifier classifier: drug therapy Components - Type Classifier * is Major topic Yes component type: qualifier classifier: physiopathology Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Double-Blind Method freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Female freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Humans freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Hypoglycemic Agents freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: adverse effects Components - Type Classifier * is Major topic No component type: qualifier classifier: therapeutic use Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Islets of Langerhans freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: drug effects Components - Type Classifier * is Major topic No component type: qualifier classifier: physiopathology Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Male freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Middle Aged freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Rosiglitazone freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Single-Blind Method freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Thiazoles freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: adverse effects Components - Type Classifier * is Major topic No component type: qualifier classifier: therapeutic use Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Thiazolidinediones freeToShare: true Components - Type Classifier * qualifier is Major topic
Rosiglitazone Clinical Trials Study Group
components (if present) include qualifier codings
11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
Computable Publishing®: MEDLINE-to-FEvIR Converter
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
National Library of Medicine, Index Section
Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary end point was change in hemoglobin A(1c); other variables assessed included fasting plasma glucose, fructosamine, endogenous insulin secretion, urinary albumin excretion, serum lipids, and adverse events. Rosiglitazone (2 and 4 mg bd) decreased mean hemoglobin A(1c) relative to placebo by 1.2 and 1.5 percentage points, respectively, and reduced fasting plasma glucose concentrations relative to placebo by 3.22 and 4.22 mmol/L, respectively. Fasting plasma insulin and insulin precursor molecules decreased significantly. Homeostasis model assessment estimates indicate that rosiglitazone (2 and 4 mg bd) reduced insulin resistance by 16.0% and 24.6%, respectively, and improved ss-cell function over baseline by 49.5% and 60.0%, respectively. Urinary albumin excretion decreased significantly in the rosiglitazone (4 mg bd) group. There was no increase in adverse events with rosiglitazone. In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions.
J Clin Endocrinol Metab 2001 Apr;86(4):1659
J Clin Endocrinol Metab. 2002 Feb;2(1):iv.
The Journal of clinical endocrinology and metabolism
Classifier added by Computable Publishing LLC
Department of Medicine, State University of New York, Brooklyn, New York 11203, USA. hlebovitz@attglobal.net